176 related articles for article (PubMed ID: 38226642)
21. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
McCurdy SR; Kanakry CG; Tsai HL; Kasamon YL; Showel MM; Bolaños-Meade J; Huff CA; Borrello I; Matsui WH; Brodsky RA; Ambinder RF; Bettinotti MP; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Biol Blood Marrow Transplant; 2018 Feb; 24(2):343-352. PubMed ID: 29055682
[TBL] [Abstract][Full Text] [Related]
22. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
23. Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation.
Salas MQ; Atenafu EG; Law AD; Lam W; Pasic I; Chen C; Dong Hwan Kim D; Michelis FV; Gerbitz A; Lipton JH; Mattsson J; Kumar R; Viswabandya A
Transplant Cell Ther; 2021 May; 27(5):428.e1-428.e9. PubMed ID: 33965185
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Rashidi A; Hamadani M; Zhang MJ; Wang HL; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn JY; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz MA; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee JW; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
Blood Adv; 2019 Jun; 3(12):1826-1836. PubMed ID: 31201170
[TBL] [Abstract][Full Text] [Related]
25. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
Bashey A; Solomon SR
Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
[TBL] [Abstract][Full Text] [Related]
26. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
27. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
29. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
[TBL] [Abstract][Full Text] [Related]
30. Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.
Esquirol A; Cadenas IG; Novelli S; Garrido A; Caballero AC; Oñate G; Lopez J; Redondo S; Argüello M; Saavedra S; Moreno C; Briones J; Sierra J; Martino R
Ann Hematol; 2024 Jan; 103(1):321-334. PubMed ID: 37971549
[TBL] [Abstract][Full Text] [Related]
31. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
Mehta RS; Saliba RM; Alsfeld LC; Jorgensen JL; Wang SA; Anderlini P; Al-Atrash G; Bashir Q; Ciurea SO; Hosing CM; Im JS; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Popat UR; Qazilbash MH; Ramdial J; Rondon G; Saini N; Srour SA; Rezvani K; Shpall EJ; Champlin RE; Alousi AM
Transplant Cell Ther; 2021 Dec; 27(12):1003.e1-1003.e13. PubMed ID: 34537419
[TBL] [Abstract][Full Text] [Related]
32. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Im A; Rashidi A; Wang T; Hemmer M; MacMillan ML; Pidala J; Jagasia M; Pavletic S; Majhail NS; Weisdorf D; Abdel-Azim H; Agrawal V; Al-Homsi AS; Aljurf M; Askar M; Auletta JJ; Bashey A; Beitinjaneh A; Bhatt VR; Byrne M; Cahn JY; Cairo M; Castillo P; Cerny J; Chhabra S; Choe H; Ciurea S; Daly A; Perez MAD; Farhadfar N; Gadalla SM; Gale R; Ganguly S; Gergis U; Hanna R; Hematti P; Herzig R; Hildebrandt GC; Lad DP; Lee C; Lehmann L; Lekakis L; Kamble RT; Kharfan-Dabaja MA; Khandelwal P; Martino R; Murthy HS; Nishihori T; O'Brien TA; Olsson RF; Patel SS; Perales MA; Prestidge T; Qayed M; Romee R; Schoemans H; Seo S; Sharma A; Solh M; Strair R; Teshima T; Urbano-Ispizua A; Van der Poel M; Vij R; Wagner JL; William B; Wirk B; Yared JA; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1459-1468. PubMed ID: 32434056
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.
Medd P; Monk I; Danby R; Malladi R; Clifford R; Ellis A; Roberts D; Hatton C; Vyas P; Littlewood T; Peniket A
Int J Hematol; 2011 Sep; 94(3):266-278. PubMed ID: 21898174
[TBL] [Abstract][Full Text] [Related]
34. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
35. Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation.
Mushtaq MU; Shahzad M; Amin MK; Lutfi F; DeJarnette S; Al-Ramahi JS; Li K; Ahmed N; Bansal R; Abdelhakim H; Shune L; Abdallah AO; Abhyankar SH; McGuirk JP; Singh AK
Leuk Lymphoma; 2024 Apr; 65(4):493-502. PubMed ID: 38164945
[TBL] [Abstract][Full Text] [Related]
36. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
[TBL] [Abstract][Full Text] [Related]
37. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis.
de Lima VJT; da Silva AF; Kerbauy LN; Kerbauy MN; Lerner D; Colares M; Ribeiro AAF; da Silva CF; Hamerschlak N; Arcuri LJ
Ann Hematol; 2022 Aug; 101(8):1795-1802. PubMed ID: 35575911
[TBL] [Abstract][Full Text] [Related]
39. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Luznik L; O'Donnell PV; Symons HJ; Chen AR; Leffell MS; Zahurak M; Gooley TA; Piantadosi S; Kaup M; Ambinder RF; Huff CA; Matsui W; Bolaños-Meade J; Borrello I; Powell JD; Harrington E; Warnock S; Flowers M; Brodsky RA; Sandmaier BM; Storb RF; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):641-50. PubMed ID: 18489989
[TBL] [Abstract][Full Text] [Related]
40. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
